The United States Food and Drug Administration (FDA) has recently approved the biosimilar for Tysabri®, developed by Sandoz. JD Supra reports this as an important milestone in biosimilar drug production.
It wasn’t long ago when the approval process and introduction of biosimilar drugs to the marketplace was moving at a slow pace, causing increasing worry among many, including some members of Congress. These biosimilar drugs are generally more affordable alternatives to often expensive biologic drugs, offering a solution to many patients and healthcare systems seeking cost-effective treatments.
This pace was especially concerning given the Trump Administration’s contemplation of a reduction in the exclusivity period for biologics, which would allow biosimilar drugs to come to market faster, and the subsequent call from senators for the Federal Trade Commission (FTC) to investigate biosimilar litigation settlement agreements reported byJD Supra.
As pharmaceutical companies including Sandoz tackle the complexities associated with developing biosimilars, and with the FDA intending to facilitate further biosimilar development, it marks a key moment for the industry. The approval of the biosimilar for Tysabri®, an expensive biologic drug, is one such significant moment.
The FDA’s recent actions potentially pave the way for more such approvals, potentially leading to increased availability of cost-effective treatments in the marketplace. This not only impacts the patients requiring these treatments but also significantly affects pharmaceutical companies, law firms, and the larger legal landscape tied to the development and patenting of biosimilar drugs.